Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: The breast cancer genome - a key for better oncology

Figure 2

Outline of implementation strategies in the clinic. Different layers of assessment of patient and tumor characteristics for treatment decision-making are shown in this schematic figure. The basis is made up of clinical staging and histopathology including important molecular markers, including estrogen (ER) and progesterone receptor (PR), HER-2 and Ki67, to categorize patients into pathological subgroups. As the resulting subgroups are heterogeneous, different molecular assays should be applied within these. Host characteristics important to the choice of treatment and optimization of dosage should be evaluated in parallel. In monitoring treatment response personalized biomarkers should be examined.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us